Navigation Links
Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
Date:1/16/2008

Cheryle R. Hart, M.D. Clarifies Previous Statement on 1/11/08

SPOKANE, Wash., Jan. 16 /PRNewswire/ -- On January 9, 2008 the FDA raised the issue regarding the use of estriol in compounded hormone replacement therapy. While awaiting further clarification, Dr. Hart suspended prescribing estriol in her medical practice. Cheryle Hart, M.D. is Mayo Clinic trained and Board certified in Ob/Gyn and founded what is now Hormones by Hart in 1997. She is also the medical director of Hormones by Hart.

Dr. Hart has been discussing this issue with medical experts in hormone replacement therapy and with some of the most experienced compounding pharmacies across the U.S. "I have learned that compounded hormone prescriptions containing estriol have been and continue to be prescribed as an important part of Hormone Replacement Therapy (HRT) throughout the United States," says Dr. Hart. The continuation of such compounding remains the subject of a major dispute between compounding pharmacies and the FDA.

The International Academy of Compounding Pharmacists (IACP) -- who represents thousands of compounding pharmacies -- says that the situation with estriol is comparable to many commonly prescribed drugs. While estriol was never formally approved by the FDA, it has a monograph from the U.S. Pharmacopeia (USP) prior to 1997. When Congress passed the FDA Modernization Act in 1997, Congress clearly indicated that drugs with a USP monograph could still be compounded when prescribed by a licensed medical practitioner.

"With this new information and clarification from the IACP, I am updating my previous intentions about prescribing compounds containing estriol," says Dr. Hart. "Until the courts give us the final word on this subject, I will continue to prescribe estriol as an important part of the total hormone replacement therapy for my patients -- whom I have found to benefit from its use. I want my patients to know that all of their prescription hormo
'/>"/>

SOURCE Cheryle R. Hart, M.D.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
7. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
10. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
11. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ -...earch report is available in its catalogue: ,, ...ctive ,, http://www.reportlinker.com/p0164368...ctive.html ,, Incubators are the most critica..., research, and other applications for providing a...
(Date:12/2/2009)..., , TUSTIN, Calif., Dec. 2 /PRNewswire-...daq: PPHM ) today reported completion of patient ...ial of Cotara® in patients with relapsed glio...rain cancer. Cotara is a targeted monoclonal anti... potential new treatment for GBM. Cotara specific...
(Date:12/2/2009)..., , CAMBRIDGE, Mass., Dec. 2 /PRNews...ther the leaders in technology development and pro...nd MEMS, announced the December 11th deadline for ..., Now in its 14th year, TechConnect World, in a...stitute (NSTI), and the Clean Technology and Susta...
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...nnounced that 105 of,its drugs have been included ..."), which was issued by China,s Ministry of Human ...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., , , , , , Other important..., , , , , , , ...se length , , Number of ,..., of the electroporation buffer , ... Influence , of temperature ,...
..., , , , , , Other important..., , , , , , , ...lse length , , Number of ,... , of the electroporation buffer , ... Influence , of temperature ,...
...l Stability of the Brinkmann Bottletop Dispenser... , , , , , , Bottletop ...de range of , different solvents from glass..., have to meet various requirements. For exa...es which may disturb trace analysis, have cytotoxi...
Other Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Optimizing electroporation parameters 6Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 2Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 3Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 4Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 5Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 6Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 7Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 8Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 9Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 10Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 11Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 12Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 13Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 14Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 15Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 16Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 17Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 18Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 19Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 20Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 21Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 22Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 23Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 24Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 25Chemical Stability of the Brinkmann Bottletop Dispenser , and the Brinkmann Bottletop Buret 26
(Date:12/2/2009)...ef, peanut butter, and other foods have done more ... safety. They also are quietly fueling a boom in t... new food safety regulations. That,s the topic of ...Chemical & Engineering News , (C&EN) ACS, weekly n...sley and Senior Correspondent Marc Reisch point ou...
(Date:12/2/2009)...it have a higher IQ and are more likely to go on t...t at the Sahlgrenska Academy and Sahlgrenska Unive...ay in the prestigious Proceedings of the National... 1.2 million Swedish men doing military service wh...oup analysed the results of both physical and IQ t...
(Date:12/2/2009)...ting the first identification of substances involv...ges harmless marine bacteria into killers that cau... Environmental Science & Technology , a semi-month...at bleaching already has destroyed up to 30 percen...earching for ways to slow or stop the damage. One ...
Breaking Biology News(10 mins):Young adults who exercise get higher IQ 2Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 1Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 2Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 3Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference 5947 4Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 1Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 2Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 3Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 4Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 5Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 6Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 7Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 8Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 9Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 10Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 11Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 12Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 13Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 14Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 15Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 16Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 17Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 18Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 19Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 20Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 21Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 22Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 23Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 24Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 25Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 26Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 27Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 28Medco Delivers Record Third Quarter 2009 GAAP Diluted EPS of 240 69 3B Diluted EPS Excluding Amortization of Intangible Assets of 240 75 5944 29VIVUS Announces Promotion of Peter Tam to President 5941 1VIVUS Announces Promotion of Peter Tam to President 5941 2VIVUS Announces Promotion of Peter Tam to President 5941 3
...io-bar-code amplification (BCA) technology, resear...inal cord have detected a protein linked in recent...pplication Read more about the bio-bar-code techno...bring sensitive DNA detection ,- Nanoparticle-Ba... of Proteins ,- Bio-Barcode Diagnostic Method Co...
...f Wisconsin research team, led by John W. Lough, P...anatomy has found that embryonic stem cells (ES ce...ue, which eventually may help doctors learn how to...ack. , The potential for ES cells to replace dama...extraordinary interest in their therapeutic applic...
... (Pleurotus ostreatus), apart from reducing choles...haracterised for its capacity for breaking down ce...or this activity ?the reason why the fungus is som...m of the PhD thesis by Arantza Eizmendi Goikoetxea...avarre with the title, Molecular Characterisation ...
Other Biology News:Nanoscale Diagnostic Sets Sights on Alzheimer's 2Nanoscale Diagnostic Sets Sights on Alzheimer's 3Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks 2Advances in the characterisation of the oyster mushroom genes 2
... Standard Tray (3 per pack), 1. One system for ge...of Coomassie Blue or silver-stain gels for protein...h sensitivity ECL detection and chromogenic detect...lume, and processing time.Proven design for consis...
DITHIOTHREITOL, 150UMOL from GE Healthcare, formerly Amersham Biosciences
Goat Anti-Human PARAINFLUENZA VIRUS 2+3 Polyclonal Antibody, Unconjugated from AbD Serotec
Culture Micro Slides, Coated from Santa Cruz Biotechnology, Inc.
Biology Products: